Horizon Therapeutics Stock Plunges on Reports FTC Will Sue to Block Amgen Deal

[ad_1]

Horizon Therapeutics


stock plunged 18% early Tuesday on reports that the Federal Trade Commission is set to challenge

Amgen


$27.8 billion deal to buy the biotech company.

[ad_2]

Source link